TECH Bio-Techne Corp

P/E 62.54
Forward P/E 34.6
Price/Sales 9.36
Beta 1.295
Div Yield 0.0044%
Market Cap --

Company Analysis

Latest News

Bio-Techne Corp Q1 2027 Earnings Preview: What Analysts Expect on November 18, 2026

Bio-Techne is expected to report Q1 2027 revenue of $284.1 million and adjusted EPS of $0.41, while the current stock price of $74.20 remains roughly 14% below...

Bio-Techne Corp Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026

For the calendar quarter ending September 30, 2026, Bio-Techne Corp is expected to report consensus revenue of $292.6 million and adjusted EPS of $0.44, with...

Bio-Techne Corp Q1 2027 Earnings Preview: What Analysts Expect on November 04, 2026

Bio-Techne is expected to report consensus revenue of $298.7 million and earnings per share of $0.40, with the current stock price of $74.20 sitting below the...

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

Bio-Techne Corporation (TECH) announced that its shareholders have voted to approve the definitive merger agreement for its acquisition by Merck KGaA,...

Bio-Techne's $73-a-Share Fate Rests With Shareholders Today — Is Merck KGaA Paying Enough?

Bio-Techne Shareholders Face a $73-a-Share Crossroads — Did Merck KGaA's Bid Leave Money on the Table? Bio-Techne shareholders convene virtually this morning...

🔴 Bio-Techne is trading N/A down in after-hours trading amid planned vote on Merck KGaA’s $73 offer

Bio-Techne is trading with Price: unavailable and % Change: unavailable in after-hours trading; its September 23, 2026 special shareholder meeting will vote on...

Wellington Management Liquidates 99.8% of Bio-Techne Stake, Despite Revenue Beat

Wellington Management Group LLP liquidated 99.8% of its Bio-Techne Corp. stake. A 13F filing dated September 13, 2026, disclosed the divestment. The firm...

Durable Capital Reduces BIO-TECHNE Stake by 89% Following Merck KGaA Buyout Agreement

In a recent 13F filing, Henry Ellenbogen's Durable Capital disclosed a significant reduction in its holdings of BIO-TECHNE CORP (TECH). The report, which...

Merck KGaA Wins German Approval for Bio-Techne Deal, Closing Late 2026

Germany’s Federal Cartel Office approved Merck KGaA’s acquisition of Bio-Techne Corp. This regulatory clearance removes a major obstacle for the pending...

Bio-Techne Corp Q4 2026 Earnings Preview: What Analysts Expect on August 05, 2026

Bio-Techne is expected to report consensus revenue of approximately $314.7 million and adjusted EPS of $0.46, while the current stock price of $72.09 remains...

Merck KGaA to Acquire Bio-Techne in All-Cash Transaction for $73.00 Per Share

Bio-Techne Corporation (TECH) has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash transaction. Upon...

Merck KGaA to Acquire Bio-Techne (TECH) in an $11.3 Billion All-Cash Transaction

Bio-Techne Corporation has entered into a definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany. The all-cash transaction values...